Literature DB >> 16774841

Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data.

F Sigala1, S Georgopoulos, E Papalambros, D Chasiotis, G Vourliotakis, A Niforou, A Kotsinas, N Kavantzas, E Patsouris, V G Gorgoulis, E Bastounis.   

Abstract

OBJECTIVES: Heregulins (HRGs) are known to induce expression of angiogenic factors such as cysteine rich-61 (CYR61) and collectively to promote neoangiogenesis. Along with extracellular matrix remodelling, mediated by matrix metalloproteinases (MMPs), these factors are important in atherogenesis. The aim of the present study was to investigate HRG, CYR61 and MMP-9 expression and their relationship with clinical and histopathological findings in carotid occlusive disease.
MATERIALS AND METHODS: Specimens of human carotid atherosclerotic plaque (n=90) were obtained by endarterectomy. Expression of HRG, CYR61 and MMP-9 was assessed by immunohistochemical and Western blot analysis. Associations between protein expression and degree of carotid stenosis, presence of symptoms, presence of an infarct in CT scan and carotid plaque histopathology were investigated.
RESULTS: An increase in HRG, CYR61 and MMP-9 expression was found, particularly in neovascularized regions of the plaques. High HRG expression was associated with the degree of carotid stenosis (p=0.028) and plaque histopathology (p=0.002). More than half of specimens from plaques with >90% stenosis had intense expression of CYR61 (p=0.047). Increased expression of MMP-9 was associated with degree of stenosis and presence of cerebral infarct on CT scan (p=0.05).
CONCLUSION: HRG, CYR61 and MMP-9 are highly expressed in human atherosclerotic carotid plaques. The association with the degree of stenosis and/or plaque histopathology implies an involvement in lesion progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774841     DOI: 10.1016/j.ejvs.2006.01.026

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  8 in total

Review 1.  CCN1/CYR61: the very model of a modern matricellular protein.

Authors:  Lester F Lau
Journal:  Cell Mol Life Sci       Date:  2011-07-31       Impact factor: 9.261

Review 2.  Matricellular protein CCN1/CYR61: a new player in inflammation and leukocyte trafficking.

Authors:  Yalin Emre; Beat A Imhof
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

3.  Emerging roles of CCN proteins in vascular development and pathology.

Authors:  Philip A Klenotic; Chao Zhang; Zhiyong Lin
Journal:  J Cell Commun Signal       Date:  2016-05-30       Impact factor: 5.782

Review 4.  Neuregulin signaling and heart failure.

Authors:  Zhenggang Jiang; Mingdong Zhou
Journal:  Curr Heart Fail Rep       Date:  2010-03

5.  CCN3 Regulates Macrophage Foam Cell Formation and Atherosclerosis.

Authors:  Hong Shi; Chao Zhang; Vinay Pasupuleti; Xingjian Hu; Domenick A Prosdocimo; Wenconghui Wu; Yulan Qing; Shitong Wu; Haneen Mohammad; Stanton L Gerson; Bernard Perbal; Philip A Klenotic; Nianguo Dong; Zhiyong Lin
Journal:  Am J Pathol       Date:  2017-06       Impact factor: 4.307

6.  Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia.

Authors:  Carrie Anna Geisberg; Guisong Wang; Radwan N Safa; Holly M Smith; Brent Anderson; Xu-Yang Peng; Brian Veerkamp; David X Zhao; Dana Blakemore; Chang Yu; Douglas B Sawyer
Journal:  Coron Artery Dis       Date:  2011-12       Impact factor: 1.439

7.  Matrix metalloproteinases in cerebral ischemia.

Authors:  Hahn Young Kim; Seol-Heui Han
Journal:  J Clin Neurol       Date:  2006-09-20       Impact factor: 3.077

8.  Overexpression of CCN3 inhibits inflammation and progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Jun Liu; Yingang Ren; Li Kang; Lihua Zhang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.